PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
238.00 - 242.07
140.53 - 242.25
26.77M / 38.44M (Avg.)
25.64 | 9.39
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
19.18%
Revenue growth above 1.5x META's 12.29%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
17.15%
Gross profit growth 1.25-1.5x META's 12.33%. Bruce Berkowitz would see if strategic sourcing or brand premium explains outperformance.
13.88%
EBIT growth 1.25-1.5x META's 10.27%. Bruce Berkowitz would verify if strategic initiatives are driving this edge.
13.88%
Operating income growth at 75-90% of META's 16.44%. Bill Ackman would demand a plan to enhance operating leverage.
40.55%
Net income growth above 1.5x META's 10.17%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
180.99%
EPS growth above 1.5x META's 10.47%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
188.14%
Diluted EPS growth above 1.5x META's 11.04%. David Dodd would see if there's a robust moat protecting these shareholder gains.
-0.66%
Both firms reduce share counts. Martin Whitman would compare buyback intensity relative to free cash flow generation.
-0.33%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
No Data
No Data available this quarter, please select a different quarter.
-9.31%
Negative OCF growth while META is at 6.39%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-22.33%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
1235.06%
Similar 10Y revenue/share CAGR to META's 1223.16%. Walter Schloss might see both firms benefiting from the same long-term demand.
1235.06%
5Y revenue/share CAGR above 1.5x META's 190.49%. David Dodd would look for consistent product or market expansions fueling outperformance.
445.26%
3Y revenue/share CAGR above 1.5x META's 77.04%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
822.37%
3Y OCF/share CAGR above 1.5x META's 125.05%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
1693.46%
Net income/share CAGR at 50-75% of META's 2770.56%. Martin Whitman might question if the firm’s product or cost base lags behind.
1693.46%
5Y net income/share CAGR above 1.5x META's 304.58%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
3224.74%
3Y net income/share CAGR above 1.5x META's 194.47%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
2361.10%
3Y equity/share CAGR above 1.5x META's 66.56%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
28.25%
AR growth well above META's 14.10%. Michael Burry fears inflated revenue or higher default risk in the near future.
-100.00%
Inventory is declining while META stands at 0.00%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
17.72%
Asset growth above 1.5x META's 5.19%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
19.14%
BV/share growth above 1.5x META's 5.80%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
No Data
No Data available this quarter, please select a different quarter.
23.73%
R&D growth drastically higher vs. META's 6.52%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
19.64%
SG&A growth well above META's 12.01%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.